Classic case of misplaced ‘bravado’

Source: Business Line

24 Aug 2015

GVK’s tangle with the EU authorities is a regulatory issue, and not a trade concern

On May 22, 2015, the European Medicines Agency (EMA) reaffirmed its recommendation to suspend a number of medicines for which bioequivalence studies were done by GVK Biosciences in Hyderabad, on behalf of several marketing authorization holders in the European Union. This was on the basis of a re-examination requested by the affected parties. And the suspension is for two years.

Continue reading

Posted in Compulsory Licensing, EU-India FTA, TRIPS plus | Leave a comment

RCEP agreement: Ministers of 16 nations to finalise modalities on August 24 in Malaysia

Source: Economic Times

18 Aug 2015

NEW DELHI: As negotiations for Regional Comprehensive Economic Partnership(RCEP) agreement progress, ministers of 16 member countries, including India and China will meet in Kuala Lumpur on August 24 to finalise the modalities of the pact.

“The talks are progressing very well. The 9th round of talks for RCEP agreement was recently concluded in Myanmar. Now in the next ministerial level meeting, the modalities would be finalised,” a senior government official told PTI.

Continue reading

Posted in Regional Comprehensive Economic Partnership | Leave a comment

Was India immature in calling off free trade talks with EU?

Source: Livemint

18 Aug 2015

A file photo of trade minister Nirmala Sitharaman. Photo: Pradeep Gaur/Mint

A file photo of trade minister Nirmala Sitharaman. Photo: Pradeep Gaur/Mint

While India intended to send a strong signal to the European Union by cancelling talks for a bilateral free trade agreement (FTA) after the European Commission imposed a ban on some Indian generic drugs, experts including former commerce secretaries hold that India may have acted in an immature manner on the matter.

Continue reading

Posted in EU-India FTA | Leave a comment

Will America’s Drug Lobby Destroy the TPP?

Source: The National Interest

18 Aug 2015

“Unfortunately, the United States seems determined to complicate this important work with petty, unreasonable demands for pharmaceutical protections.”

For all the talk about the Trans-Pacific Partnership being a high-standard agreement that will set the rules for trade in the 21st Century, the trickiest and most important negotiations have revolved around very traditional trade barriers. Protections for agricultural products, automobiles, and apparel are as politically intractable as they are harmful to the economies of the region. How negotiators are able to resolve these issues has significant bearing on the ultimate value of the TPP.

Continue reading

Posted in data exclusivity, Trans-Pacific Partnership Agreement | Leave a comment

India, US to hold key commercial dialogue next month

Source: The Times of India

13 Aug 2015

NEW DELHI: India and the US will hold first-ever high-level strategic and commercial dialogue next month in Washington focusing on areas such as ease of doing business and smart cities with an aim to boost investment and raise bilateral trade five-fold to US $ 500 billion annually.

Continue reading

Posted in Compulsory Licensing, IP Rights | Leave a comment

Regional cooperation pact talks: China demands more concessions from India, Japan

Source: Business Line

13 Aug 2015

Beijing holds up pact in goods; India fears import surge from China

China has emerged as India’s toughest adversary at the on-going Regional Comprehensive Economic Partnership pact being negotiated between 16 countries including the 10-member Asean.

Beijing blocked a preliminary agreement on goods market liberalisation at last week’s round in Nay Pyi Taw, insisting that New Delhi and Tokyo improve their initial offers in the area, a government official told BusinessLine.

Continue reading

Posted in Regional Comprehensive Economic Partnership | Leave a comment

EU hoping for solution after FTA talks stalled over drug ban

Source: The Economic Times

NEW DELHI: The European Union today defended its decision to ban around 700 generic drugs clinically tested by GVK Biosciences which had prompted India to defer the talks with the 28-nation bloc on the proposed free trade agreement.

Continue reading

Posted in EU-India FTA | Leave a comment